In the modern Uterine Fibroid Market, treatment success is no longer judged solely by fibroid shrinkage or surgical necessity, but primarily by the improvement in the patient's Health-Related Quality of Life (HRQoL). The gold standard for measuring this impact is the validated, condition-specific Uterine Fibroid Symptom and Quality of Life (UFS-QoL) questionnaire. This patient-reported outcome...